MIAMI LAKES, Fla.--(BUSINESS WIRE)--Sep 10, 2025--

Segal Trials announced its participation as a clinical research site in the pivotal studies that supported the U.S. Food and Drug Administration’s (FDA) approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults. This milestone, announced by Tonix Pharmaceuticals, marks the first new FDA-approved therapy for fibromyalgia in more than 16 years.

Dr. Olga Lapeyra , Principal Investigator at Segal Trials, provided leadership during the study.

“Fibromyalgia has long been a condition with limited treatment options, leaving patients and families searching for relief,” said Dr. Lapeyra. “This approval represents renewed hope for the millions of individuals who live with this disorder. To see a n

See Full Page